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ABSTRACT
Breast cancer is one of the leading causes of death worldwide, and therefore, 
new and improved approaches for the treatment of breast cancer are desperately 
needed. CtIP (RBBP8) is a multifunctional protein that is involved in various cellular 
functions, including transcription, DNA replication, DNA repair and the G1 and G2 
cell cycle checkpoints. CtIP plays an important role in homologous recombination 
repair by interacting with tumor suppressor protein BRCA1. Here, we analyzed the 
expression profile of CtIP by data mining using published microarray data sets. We 
found that CtIP expression is frequently decreased in breast cancer patients, and 
the patient group with low-expressing CtIP mRNA is associated with a significantly 
lower survival rate. The knockdown of CtIP in breast cancer MCF7 cells reduced Rad51 
foci numbers and enhanced g H2AX foci formation after g-irradiation, suggesting that 
deficiency of CtIP decreases homologous recombination repair and delays DNA double 
strand break repair.
To explore the effect of CtIP on PARP inhibitor therapy for breast cancer, CtIP-
depleted MCF7 cells were treated with PARP inhibitor olaparib (AZD2281) or veliparib 
(ABT-888). As in BRCA mutated cells, PARP inhibitors showed cytotoxicity to CtIP-
depleted cells by preventing cells from repairing DNA damage, leading to decreased 
cell viability. Further, a xenograft tumor model in mice with MCF7 cells demonstrated 
significantly increased sensitivity towards PARP inhibition under CtIP deficiency. In 
summary, this study shows that low level of CtIP expression is associated with poor 
prognosis in breast cancer, and provides a rationale for establishing CtIP expression 
as a biomarker of PARP inhibitor response, and consequently offers novel therapeutic 
options for a significant subset of patients.
INTRODUCTION
Breast cancer is the most frequently diagnosed 
cancer and one of the leading causes of cancer-associated 
deaths in women. Incidence rates have risen over the past 
20 years in industrialized countries [1]. Therefore, the 
development of mechanism-based, targeted combination 
therapy that helps to improve disease-free survival and 
overall survival of breast cancer patients is still a major 
challenge.
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Cells are continuously exposed to exogenous agents 
and biological processes that create DNA damage, which, 
if not repaired effectively and efficiently, can lead to 
genomic instability or cell death [2]. Poly(ADP-ribose) 
polymerase-1 (PARP-1) is an abundant nuclear enzyme that 
synthesizes the poly(ADP-ribose) polymer when activated 
by DNA single strand breaks (SSBs) [3]. Once single strand 
break (SSB) and double strand break (DSB) damage of 
DNA are produced, PARP-1 binds to the DNA and rapidly 
recruits x-ray repair complementation group 1(XRCC1) 
and tyrosyl DNA phosphodiesterase 1 (TDP1) to the site of 
damage to catalyze subsequent repair [4]. Repair of DSBs 
can be undertaken by two main pathways: homologous 
recombination (HR) repair (HRR) and non-homologous 
end-joining (NHEJ) repair [5]. BRCA1 and BRCA2 
proteins normally function as important components 
of the HR pathway for the repair of DSBs. It has been 
reported that PARP inhibition leads to accumulation of 
DSBs by the failure of SSB repair and by replication fork 
collapse, which in turn requires HR-mediated repair [6-8]. 
In addition to blocking PARP catalytic activity at SSBs, 
PARP inhibitors can trap PARP enzyme at damaged DNA 
to form PARP-DNA complexes, which are more cytoxic 
[9]. PARP inhibition also leads to attenuation of alternative 
end joining repair through suppression of DNA polymerase 
θ recruitment [10, 11]. Cancers with BRCA1/2 mutations 
are defective in HRR and are therefore hypersensitive 
to PARP inhibitors [7]. Following this approach, recent 
clinical trials for the treatment of BRCA1/BRCA2-deficient 
breast and ovarian tumors using specific inhibitors targeting 
PARP have been performed with the concept of ‘synthetic 
lethality’ [4, 6, 12, 13]. However, whether synthetic 
lethality is applicable to human cancers that have acquired 
other mutations/deletions in DNA repair genes has not been 
widely investigated.
Because CtIP (CtBP-interacting protein), which 
functions in the initial step of HRR with NBS1 and 
BRCA1 by acting as an end-resection enzyme to produce 
3’-single stranded DNA, is known to be frequently 
downregulated in breast cancers as well as in other types 
of cancers, we focused on CtIP in this study and showed 
that breast cancer cells with defects in CtIP function 
are hypersensitive to the PARP inhibitors olaparib and 
veliparib. Thus, PARP inhibitors have therapeutic potential 
in the treatment of CtIP-deficient breast cancers, and our 
results might extend the concept of synthetic lethality to 
tumors bearing alterations in CtIP.
RESULTS
CtIP expression is frequently down-regulated in 
breast cancers
CtIP association with BRCA1 facilitates HRR of 
DSBs by initiating DNA resection [14]. Cells defective 
in CtIP are highly sensitive to topoisomerase I/II poisons 
and ionizing radiation (IR) and are unable to repair Spo11-
capped meiotic DSBs [15-20]. Therefore, we investigated 
the relationship of CtIP expression in breast cancers and 
their clinical outcome by using two publicly available 
microarray datasets in the Gene Expression Omnibus 
(GEO) database (GSE10780 [21] and GSE3744 [21]) 
that contain both normal and breast cancer samples. 
CtIP expression levels were measured as log2 (probe 
intensities) using Affymetrix microarrays. In both these 
two datasets, the levels of CtIP mRNA in breast cancers 
were statistically lower than those in normal breast tissues 
(Fig.1A and Supplemental Fig.1A). Because patients 
diagnosed with triple negative breast cancer (TNBC) 
have a higher risk of disease relapse within 5 years than 
patients treated for other breast cancer subtypes [22], 
we compared the CtIP mRNA level in TNBC to that in 
non-TNBC by using one publicly available microarray 
dataset (GSE47561 [23]). We found that CtIP expression 
was significantly lower in triple negative breast cancer 
(Fig.1B), which is consistent with the previous study 
[24]. These results indicate that the expression level of 
CtIP is decreased in breast cancers. Furthermore, CtIP 
gene alterations were observed in several cancer types 
with either mutation, deletion or copy number variation 
(Supplemental Fig. 1C). However, the incidence of 
deletion or mutation of CtIP was rather low in cancers. 
We thus speculated that CtIP down-regulation might be 
due to epigenetic or posttranscriptional regulation.
To determine the clinical impact of reduced CtIP 
expression in human breast cancer, we assessed the 
association between CtIP mRNA levels and clinical 
outcome in three independent breast cancer cohorts 
[25-27] with clinical information (GEO database). To 
investigate the prognostic impact of CtIP expression in 
breast cancer, breast cancer patients were categorized into 
two groups based on CtIP mRNA expression. We found 
that patients with cancers displaying low CtIP expression 
levels had significantly shorter overall survival compared 
to those with high CtIP (Fig. 1C-1D, Supplemental Figure 
1B). Additionally, we confirmed the correlation between 
CtIP expression and clinicopathological variables. 
Clinical data from GEO dataset GSE3494 was used for 
this analysis [25]. The samples pooled in the dataset 
were divided into two groups according to the expression 
level of CtIP in tumor tissue and χ 2 test was performed. 
As shown in Table  1, low level of CtIP expression was 
associated with p53 mutation (P=0.0025), PR status 
(P=0.0312), larger tumor (P=0.0082) and lymph nodes 
metastasis (P<0.0001). It is notable that there was an 
association of high CtIP with low PR in dataset of 
GSE3494, whereas no correlation was observed with ER 
status and information of Her2 status was not available. 
We calculated the data from publically available gene 
expression profile (GSE10780, GSE47561, GSE3494 
and GSE21653). Because these datasets did not include 
detailed information about BRCA status, radiation therapy 
or chemotherapy including use of PARP inhibitor, we 
could not analyze the correlations between these factors 
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Figure 1: The expression of CtIP is decreased in human breast cancers. A. CtIP mRNA expression levels are significantly 
reduced in breast tumors in comparison to normal breast tissues, using the publicly available microarray dataset GSE10780. CtIP expression 
is measured as log2 (probe intensities). The P-values were obtained from Mann-Whitney U or Kruskal-Wallis tests. B. The CtIP mRNA 
expression levels are further decreased in triple-negative breast cancers (TNBC), compared to non-triple negative breast cancers (Non-
TNBC), in the publicly available microarray dataset GSE47561. CtIP expression is presented in log2 (probe intensities) scale. The P-values 
were obtained from Mann-Whitney U or Kruskal-Wallis tests. C. Kaplan-Meier survival curves comparing disease-free survival between 
cases with the lowest (≤ 20th percentile) vs. highest (> 20th percentile) CtIP expression (P = 0.018, log-rank test) (GSE3494). D. Kaplan-
Meier survival curves comparing disease-free survival between cases with the lowest (≤ 20th percentile) vs. highest (> 20th percentile) CtIP 
expression (P = 0.0084, log-rank test) (GSE21653).
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and low level of CtIP expression. As shown in the Table 1, 
the low expression of CtIP is highly associated with 
lymph nodes metastasis, which could be one of the reasons 
for the low survival rate in CtIP low expression patients, 
although we do not know the mechanism in details. We 
further examined the correlation between CtIP expression 
and clinical stage in breast cancer using the data from 
GSE61304. Even though the expression of CtIP seemed to 
be at a lower level in higher T stage, it was not statistically 
significant (data not shown). Taken together, these findings 
suggest that CtIP downregulation has a critical role in 
overall patient survival.
Loss of CtIP results in DSB repair defect
HRR-mediated DSB repair is carried out in a series 
of steps, the first step is nucleolytic processing, which 
generates 3’ single-stranded DNA (ssDNA) tails to initiate 
strand invasion [28, 29]. The 3’ single-stranded stretch of 
DNA is coated with a single-strand binding protein known 
Table 1: The correlation between CtIP expression and clinicopathological variables
Characteristics No. of patients Expression Chi-square value P value
High Low
Age/year
 <55 75 62 13 0.45 0.5029
 ≥55 176 139 37
p53 status
 Positive 58 47 11 0.04 0.8355
 Negative 193 154 39
p53 mutation
 Yes 72 49 23 9.15 0.0025
 No 179 152 27
ER status
 Positive 213 174 39 2.27 0.1317
 Negative 34 24 10
PR status
 Positive 190 158 32 4.64 0.0312
 Negative 61 43 18
Histologic grade
 1 67 58 9 4.94 0.0847
 2 128 103 25
 3 54 38 16
Tumor size, d/cm
 ≥2 139 103 36 6.98 0.0082
 <2 112 98 14
Lymph nodes metastasis
 Yes 84 54 30 19.06 <0.0001
 No 158 139 19
Data are presented as number.
ER: Estrogen receptor; PR:Progesterone receptor.
Features of breast cancer(χ2 text was used), using the public expression datasets GSE3494. CtIP expression is measured as 
log2 (probe intensities).
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as replication protein A (RPA), which is in turn displaced 
by RAD51 [30]. CtIP is reported to initiate 5’-strand end 
resection to generate 3’-overhang, which is required for 
the effective formation of the RPA-ssDNA complex [14]. 
This was further supported by a result from GSEA analysis 
of human breast cancers (Supplemental Fig. 2A), showing 
that at least 50% of the gene sets were associated with 
DNA damage response and repair. Detection of γH2AX 
has been suggested as a highly specific and sensitive 
marker for monitoring DSB damage and resolution [31]. 
Therefore, we quantified γH2AX foci formation after CtIP 
knockdown (Fig. 2A). As shown in Figure 2B and 2C, 
one hour after IR, the number of γH2AX foci was almost 
the same as at an early time point, but rather higher 24 
hr later in CtIP-depleted MCF cells, when compared to 
control MCF7 cells, which suggested that the efficiency 
of DSB repair was reduced when CtIP was dysfunctional. 
Further, we checked HRR efficiency by checking Rad51 
foci, and we found that in CtIP-depleted MCF cells, the 
number of Rad51 foci was significantly reduced 3 hrs after 
4 Gy irradiation (Fig. 2D and 2E). These observations 
suggest that without CtIP, DNA end resection is blocked 
and DSBs cannot be repaired precisely and effectively 
by HRR.
Figure 2: Loss of CtIP causes HRR deficiency. A. Western blot analysis of CtIP in whole cell extracts from MCF7 cells transfected 
with CtIP or control siRNA (25 nM) for 48 hrs. B. The images of γH2AX foci after 4 Gy IR in control (NC) and CtIP-depleted MCF7 cells at 
different time points as indicated. Scale bar, 40 μm. C. Quantification of γH2AX foci in Figure 2B. Numbers of γH2AX foci were quantified 
from triplicated experiments (>50 cells at each condition) and are shown as mean values ± SEM. Statistical significance was calculated by 
one-way analysis of variance (ANOVA). ( * for P<0.05; ** for P<0.01; where not indicated, the P value was equal or higher than 0.05).
(Continued )
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Loss of CtIP causes cells to be sensitive to PARP 
inhibitors
Because CtIP-depleted cells show HRR defect, they 
are expected to be more sensitive to PARP inhibitors. Here, 
we used two clinically used PARP inhibitors olaparib and 
veliparib to examine this point. The result showed that 
CtIP-depleted MCF7 cells indeed exhibited significantly 
increased DNA damage after treatment with these PARP 
inhibitors (Fig. 3A, 3B and Supplemental Fig. 3A and 
B), which was consistent with the recent study in ovarian 
cancer cells [32]. When we analyzed cell viability after 
treatment with olaparib and veliparib, CtIP-depleted cells 
showed decreased cell viability with MTT assay (Fig. 3C) 
and in colony formation assay (Fig. 3D), which was similar 
to BRCA1 deficient cells (Supplemental Fig. 3D and E) 
[7, 33]. It was reported that in BRCA1 deficient cancer 
cells, loss of 53BP1 leads to PARP inhibitor resistance 
[34, 35], therefore we checked whether the loss of 53BP1 
can also cause PARP inhibitor resistance in CtIP-depleted 
cells. As shown in Fig. 3E and 3F, we found that loss of 
53BP1 itself leads to sensitization to a PARP inhibitor, and 
the loss of CtIP causes cells to be highly sensitive to a 
PARP inhibitor, however, double loss of 53BP1 and CtIP 
can result in resistance to a PARP inhibitor compared to 
the loss of CtIP. This observation therefore substantiates 
the finding that loss of CtIP is associated with sensitivity 
towards PARP inhibition.
CtIP loss results in increased PARP inhibitor 
sensitivity in vivo
To assess the therapeutic effect of olaparib on CtIP-
depleted cells in vivo, we investigated the ability of olaparib 
to suppress the growth of a CtIP-depleted MCF7 cell line-
derived xenograft tumor. MCF7 or CtIP-depleted MCF7 
cells were subcutaneously grafted into Balb/c nude mice. 
Two days after transplantation, mice were treated daily with 
olaparib or a vehicle. At day 3, olaparib treated two groups 
(siControl (black line) and siCtIP (violet line)) showed 
a slightly lower growth, compared to the group without 
olaparib treatment (siControl (green line) and siCtIP (red 
Figure 2 (Continued ): D. Wild-type and CtIP-depleted MCF7 cells were irradiated (4 Gy) and fixed 3 hrs later. Rad51 and γH2AX foci 
were immunodetected with anti-Rad51 and anti-γH2AX antibodies, respectively. Cell nuclei were counterstained with DAPI. Scale bar, 
10 μm. E. Quantification of Rad51 foci in Figure 2D. 50 cells at each condition were calculated. Mean ± SEM. Statisitcal significance, 
** for P<0.01.
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line)), although it was not statistically significant (Fig. 4A). 
This decreased growth could be due to the effect of olaparib, 
as we observed that the plating efficiency was slightly 
decreased from 75% to 67 % in the presence of olaparib as 
described in Fig. 3D legend. Sixteen days after treatment, 
olaparib caused a clearly and statistically significant 
inhibitory effect on tumor volume in CtIP-depleted MCF7 
xenografts (Fig. 4A and 4B). The tumor weight was much 
Figure 3: Loss of CtIP causes cells to be sensitive to PARP inhibitor. A. PARP inhibitor showed augmented DSB DNA damage 
in CtIP-depleted MCF7 cells. Two μM of olaparib were added to wild-type MCF7 cells and CtIP-depleted MCF7 cells and cultured for 
16 hrs. Cells were then fixed and immunostained with γH2AX antibodies. Scale bar, 10 μm. B. Quantification of γH2AX foci in Figure 3A. 
Numbers of γH2AX foci were quantified from triplicated experiments (>50 cells at each condition) and are shown as mean values ± SEM. 
Significance was calculated by one-way analysis of variance (ANOVA) ( * for P<0.05; ** for P<0.01; where not indicated, the P value was 
higher than 0.05). C. Cells were incubated with various concentrations of olaparib and veliparib, and cell viability was determined by CCK 
assay 96 hrs later. Plotted values are the mean values ± SEM from three independent experiments.
(Continued )
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less in olaparib-treated CtIP-depleted MCF7 xenografts, 
when compared to vehicle treatment or other groups on 
day 16 (Fig. 4B). During this period, we noted that in the 
xenograft experiment, each of the treatment regimes was 
equally well tolerated, with none of the mice showing 
significant changes in bodyweight (Fig 4C).
Figure 3 (Continued ): D. Knockdown of CtIP reduces colony formation after PARP inhibitor treatment in MCF7 cells (left, olaparib; 
right, veliparib). Colony formation was carried out in triplicate and survival rate is calculated as mean values ± SEM. The plating efficiency 
of NC and siCtIP was 75 ± 2 % and 67 ± 2 %, respectively for the left olaparib graph. The plating efficiency of the NC and siCtIP was 85 
± 3 % and 60 ± 4 %, respectively for the right veliparib graph. E. Western blot analysis of 53BP1 in whole cell extracts from MCF7 cells 
transfected with 53BP1, 53BP1/CtIP or control siRNA for 48 hrs. F. Loss of 53BP1 rescues colony formation in CtIP-depleted MCF7 cells 
after treatment with PARP inhibitor olaparib. Plotted values are the mean values ± SEM from three independent experiments. The plating 
efficiency of NC, siCtIP, si53BP1, and siCtIP/53BP1 was 95 ± 2 %, 80 ± 2 %, 46 ± 3 %, and 50 ± 4 %, respectively. 
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Figure 4: AZD2281 treatment decreased growth of MCF7 xenograft tumor. A. Loss of CtIP significantly reduces xenograft 
growth after PARP inhibitor olaparib treatment. A total of 1× 10 7 cells of MCF7 cells or CtIP-depleted MCF7 cells were injected into 
the backs of nude mice (n = 6 for each group). Tumor-bearing animals were intraperitoneally injected daily with olaparib (50 mg/kg) or 
DMSO. Xenograft size was measured every 3 days. Quantitated xenograft volume is shown (error bars represent SEM). Significance was 
calculated by one-way analysis of variance (ANOVA) ( * for P<0.05; ** for P<0.01). Arrows show the dates when the mice were treated 
with the drugs. Because tumor cells were injected with equal volume of Matrigel, which remained to be present, the xenograft volume 
contained that of Matrigel. B. Tumor weight was measured after 16 days treatment with olaparib in each cohort. Quantification of tumor 
weight is shown (error bars represent SEM). Significance was calculated by one-way analysis of variance (ANOVA) ( * for P<0.05; ** for 




In recent years, several PARP inhibitors have 
been developed and subjected to clinical trials for the 
treatment of cancer [36-38]. Using PARP inhibitors as 
the synthetic lethal approach represents a powerful new 
strategy for therapeutic intervention [39, 40]. Recently 
Lin et al. showed that CtIP knockdown sensitized 
ovarian cancer cells to olaparib [32]. Here, we found 
that CtIP-depleted breast cancer cells show enhanced 
sensitivity to PARP inhibitors olaparib and veliparib. 
In agreement with an underlying defect in DDR, siRNA 
targeting CtIP caused a concomitant increase and 
persistence in γH2AX formation and impaired DNA 
damage-induced Rad51 foci formation. This suggested 
that the cause of PARP inhibitor sensitivity in cells 
depleted of CtIP might involve a defect in DNA end-
resection, which led to dysfunctional HR. We further 
showed the double loss of 53BP1 and CtIP can result 
in resistance to a PARP inhibitor compared to the loss 
of CtIP. The CtIP deficiency caused severe HRR defect 
probably at the initiation process, and the 53BP1 
deficiency under CtIP knockdown condition may have 
partially rescued HRR but have a defect in NHEJ repair. 
This condition thus resulted in a slightly lower survival 
compared with the 53BP1 deficiency alone, where 
NHEJ is defective but HR is active. This observation is 
consistent with the notion that 53BP1 cooperating with 
RIF1 and PTIP promotes NHEJ repair [41] and thus 
its absence negatively affects the sensitivity to a PARP 
inhibitor in MCF-7 cells.
The human CtIP is a nuclear protein which is 
widely expressed in various human tissues [42]. It is 
phosphorylated upon DNA damage (possibly by ATM/
ATR), cooperates with the Mre11-Rad50-Nbs1 complex 
and BRCA1 in processing DSB broken ends [14, 43, 
44]. It promotes HR by initiating DSB end resection 
and the formation of ssDNA [30]. Finally RAD51–
ssDNA nucleoprotein filament is formed to promote 
strand invasion and HR. In the absence of BRCA1 or 
CtIP, RAD51 binding to DSB sites and the HR process 
are interfered with, resulting in mutagenic DNA repair, 
genome instability, and tumorigenesis [45]. In CtIP-
deficient mice, early embryonic lethality and shortened life 
span are observed with the development of multiple types 
of tumors [46]. Furthermore, CtIP deficiency was found 
to be associated with a significantly increased mutation 
rate in a screening study of colon cancers [47]. From a 
mutation screening of the CtIP gene in 89 human tumor 
cell lines, 5 missense and 11 silent mutations were found 
[48]. Meanwhile, it has been reported that CtIP protein 
level was frequently quite low in breast cancer cells, 
especially in estrogen receptor negative breast cancers 
[24]. Furthermore, a recent study showed that CtIP was 
also widely mutated in patients with myelodysplastic 
syndrome (MDS) and acute myeloid leukemia (AML) 
(MDS/AML) [49]. All these findings reveal that CtIP plays 
an important role in tumorigenesis.
In conclusion, CtIP is frequently downregulated 
in breast cancer cells and our studies revealed that the 
expression level of CtIP in breast cancer patients is 
correlated with overall survival. Loss of CtIP results in 
HRR defect, providing the rationale to investigate the 
clinical significance of CtIP and its potential use as a 




MCF7 cells were cultured in RPMI 1640 medium 
(Invitrogen) containing 10% FCS (Hyclone), 100 U/ml 
penicillin and 100 μg/ml streptomycin (Gibco). All cells 
were grown at 37°C in a humidified atmosphere with 5% 
CO2.
Cell proliferation assay (MTT assay)
Cells were seeded in 96-well plates in triplicate 
at densities of 5 × 103 per well. Cell proliferation was 
monitored at desired time points. In brief, the MTT 
assay was performed using a CCK-8 assay kit (Dojindo) 
by adding 10 μl of CCK-8 reagent for 4 hrs. Light 
absorbance of the solution was measured at 450 nm 
with a reference of 600 nm, using a microplate reader 
(TECAN).
Colony formation assay
MCF7 cells were seeded in triplicate in 6-cm dishes 
in complete medium. After 10-14 days of growth, cells 
were fixed and stained with 0.1% crystal violet, and visible 
colonies were counted to determine cell numbers in each 
colony.
Western blot analysis
Cells at 90% confluency in the 6-cm dishes were 
lysed in lysis buffer. Whole cell extracts were separated 
by 10% sodium dodecylsulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE) and electroblotted to 
PVDF membrane (Bio-Rad). Membranes were incubated 
with appropriate primary antibodies diluted in 5% skim 
milk (in PBS) overnight at 4°C. The membranes were 
further incubated with secondary antibodies for 1 hr at 
room temperature. The membranes were then reacted 
with a chemiluminescent reagent (Millipore) and 




For foci analysis, MCF7 cells were irradiated (4 Gy) 
and left to recover for different times. Cells were incubated 
with PARP inhibitors olaparib (Selleckchem) or veliparib 
(Selleckchem) where indicated. Cells were fixed with 10% 
formalin neutral buffer at room temperature for 15 min, 
permeabilized with 0.1% Triton X-100/PBS (phosphate 
buffered saline) on ice for 5 min, blocked with 10% FBS/
PBS, and incubated with primary antibodies diluted in 
10% FBS/PBS at room temperature for 1 hr. Primary 
antibodies were detected by anti-mouse Alexa 488 or anti-
rabbit Alexa 594 secondary antibodies (Molecular Probes). 
Nuclei were stained by 4’,6-diamidino-2-phenylindole 
(DAPI). Immunofluorescence images were captured using 
a Fluoview FV10i microscope (Olympus).
siRNA transfection
Transfection with dsiRNA (Integrated DNA 
Technologies) was carried out using Lipofectamine® 
RNAiMAX (Invitrogen) as recommended by the 
manufacturers. Negative Control (DS NC1) siRNAs 
were used as negative controls (Integrated DNA 
Technologies). Human siCtIP target sequence is 5′- 
GCTAAAACAGGAACGAATCTT-3′.
Xenograft experiments
MCF7 cells (1.0 × 107) in 0.2 ml of growth 
medium containing 50% volume of Matrigel (BD 
Biosciences) were subcutaneously injected into the 
back of the Balb/c nude mice (Japan SLC, Inc.). Two 
days after transplantation, mice were treated daily with 
either a vehicle or 50 mg/kg bodyweight of olaparib 
intraperitoneally. Tumor size was measured every 3 days 
and calculated using the V=1/2(L X W2) formula. All 
animal studies were performed in accordance with the 
Guidelines for Animal Experiments of the National Cancer 
Center, which meet the ethical guidelines for experimental 
animals in Japan.
Quantification of foci
All images were captured at identical exposures 
selected so as to avoid saturation at any individual focus. 
Intra-nuclear foci were counted by hand from confocal 
images. Foci from approximately 50 cells were scored for 
each time point in 3 independent experiments.
GSEA
Gene Set Enrichment Analysis (GSEA) was 
performed by the JAVA program. Breast cancer patient 
gene profiling data (GSE47561) was obtained from the 
Gene Expression Omnibus (GEO) site. The patients 
were classified into two groups according to their CtIP 
expression level (top 50%: high vs. bottom 50%: low) 
and GSEA was carried out to assess the effects of CtIP 
expression level on various biological activities using 
these two classified data sets. One thousand random 
sample permutations were carried out and significantly 
enriched gene sets were identified, which produced a 
nominal P-value < 0.05 and false discovery rates (FDR) 
< 0.25.
Statistical analysis
Statistical significance of differences between 
different groups was determined using the Studentʼs t-
test. The Kaplan-Meier method was used to estimate 
survival curves for human patients. The log-rank test 
and Wilcoxon test were used to compare the differences 
between curves. The chi-square test was applied to 
analyze the clinicopathological features of breast cancer. 
The mutation counts and fraction of copy number 
altered genome data for TCGA individuals were directly 
downloaded from the cBioPortal for Cancer Genomics 
(http://cbioportal.org).
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